Conversion of a portion of the loans from Highbridge and Whitebox and
Information on the Total Number of Voting Rights (denominator)
Liege, Belgium, 17 August 2022 – 17:45 CET – Mithra Pharmaceuticals SA (Euronext Brussels:
MITRA) (the "Company" or "Mithra"), a company dedicated to Women’s Health, today announces that,
following the first drawdown by the Company under the loan facility concluded with funds managed
by Highbridge Capital Management, LLC ("Highbridge") and funds managed by Whitebox Advisors, LLC
("Whitebox", and together with Highbridge, each a “Lender”), another portion of the loans was
contributed in kind by Whitebox against the issuance of new shares.
Following the first drawdown, another portion of the loans (including accrued interest, as relevant, and
an option payment amount) was contributed in kind for an aggregate amount of EUR 402,149.77
through the issuance of 61,913 new shares at an issue price of ca. EUR 6.50 per share.
On 8 August 2022, the Company and the Lenders entered into a three year term senior secured
convertible facilities agreement for an amount of up to EUR 100,000,000, which can be drawn in three
tranches. The first tranche of EUR 50,000,000 was drawn upon signing of the agreement. Following
the last contribution in kind, the outstanding principal amount of the loans already drawn is
EUR 43,050,000.00.
In accordance with article 15 of the Belgian Act of 2 May 2007 on the disclosure of major participations
in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous
provisions, following this capital increase’s completion Mithra now has 51,843,699 outstanding shares
carrying voting rights (against 51,781,786 outstanding shares carrying voting rights previously).
Therefore, Mithra publishes the following updated information:
• Capital: EUR 37.954.551,73
• Total number of securities carrying voting rights: 51,843,699 (all ordinary shares)
• Total number of voting rights (= denominator): 51,843,699 (all relating to ordinary shares)
• Number of outstanding rights to subscribe to securities carrying voting rights:
o Pursuant to the share option plan of 5 November 2018: 1,394,900 subscription rights
giving right to 1,394,900 ordinary shares
o Pursuant to the share option plan of 22 July 2020: 690,000 subscription rights giving
right to 690,000 ordinary shares
o Pursuant to the share option plan granted to the lending shareholders of 7 September
2020: 300,000 subscription rights giving right to 300,000 ordinary shares
o Pursuant to the share option plan of 20 November 2020: 390,717 subscription rights
giving rise to 390,717 ordinary shares.
*******